IceCure Medical Ltd. (NASDAQ:ICCM) Receives Average Recommendation of “Hold” from Brokerages

IceCure Medical Ltd. (NASDAQ:ICCM) has received a consensus rating of “Hold” from the four research firms that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation and two have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $30.00.

ICCM has been the subject of a number of recent research reports. Wall Street Zen cut shares of IceCure Medical from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. Zacks Research cut IceCure Medical from a “hold” rating to a “strong sell” rating in a report on Friday, August 14th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a research note on Friday, July 17th.

IceCure Medical Stock Performance

NASDAQ:ICCM opened at $1.15 on Thursday. The stock has a market capitalization of $3.94 million, a PE ratio of -0.14 and a beta of 0.43. IceCure Medical has a fifty-two week low of $1.09 and a fifty-two week high of $30.30. The company has a fifty day moving average of $2.30 and a two-hundred day moving average of $5.35.

IceCure Medical (NASDAQ:ICCM) last released its quarterly earnings results on Tuesday, June 30th. The company reported ($1.60) earnings per share for the quarter. IceCure Medical had a negative return on equity of 174.26% and a negative net margin of 427.67%.The company had revenue of $0.91 million for the quarter. Research analysts forecast that IceCure Medical will post -4.61 earnings per share for the current year.

About IceCure Medical

IceCure Medical Ltd. is an Israel-based medical device company that develops minimally invasive cryoablation technology for the treatment of tumors. The company’s technology uses liquid nitrogen to freeze and destroy targeted tissue, with the goal of providing an alternative to more invasive surgical procedures.

Its primary product, the ProSense system, is designed to deliver controlled cryoablation through a thin probe inserted into a tumor under image guidance. The system has been developed for use in a range of tumor types, including breast, kidney, liver, lung and bone tumors, and has received regulatory clearances and approvals for certain indications in markets including the United States and other countries.

IceCure Medical is headquartered in Caesarea, Israel, and serves healthcare providers through commercial and distribution activities in international markets, including North America, Europe and Asia.